All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Bookmark this article
During the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE. We asked, What is the latest data from REACH-3 for ruxolitinib treated patients with steroid refractory chronic graft versus host disease (SR-cGvHD) after crossover?
What is the latest data from REACH-3 for ruxolitinib treated patients with SR-cGvHD after crossover?
Zeiser begins by explaining the motivation behind REACH-3 and goes on to outline its study design. He then provides insights on the efficacy and tolerability data presented at the 49th Annual Meeting of the EBMT, including response rates and comparisons with existing safety profiles. Zeiser concludes by detailing the applications of ruxolitinib in patients with steroid refractory chronic GvHD who have not responded to other systemic therapies.
More information on the REACH-3 clinical trial can be found on the GvHD Hub, here.
Ruxolitinib is approved by the European Commission for the treatment of patients with SR-GvHD
On May 5, 2022, the European Commission announced the approval of ruxolitinib, a JAK1/2 inhibitor, for treatment of patients aged ≥12 years with acute or...
FDA approval of ruxolitinib for the treatment of patients with chronic GvHD
On September 22, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of ruxolitinib for the treatment of patients with chronic...
Subscribe to get the best content related to GvHD delivered to your inbox